GeneOne Life Science Balance Sheet Health
Financial Health criteria checks 6/6
GeneOne Life Science has a total shareholder equity of ₩113.6B and total debt of ₩10.6B, which brings its debt-to-equity ratio to 9.3%. Its total assets and total liabilities are ₩151.9B and ₩38.3B respectively.
Key information
9.3%
Debt to equity ratio
₩10.55b
Debt
Interest coverage ratio | n/a |
Cash | ₩8.67b |
Equity | ₩113.60b |
Total liabilities | ₩38.34b |
Total assets | ₩151.94b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A011000's short term assets (₩32.8B) exceed its short term liabilities (₩20.3B).
Long Term Liabilities: A011000's short term assets (₩32.8B) exceed its long term liabilities (₩18.1B).
Debt to Equity History and Analysis
Debt Level: A011000's net debt to equity ratio (1.7%) is considered satisfactory.
Reducing Debt: A011000's debt to equity ratio has reduced from 43.9% to 9.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A011000 has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A011000 is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.